Capstone Therapeutics Corp
OTC:CAPS
Capstone Therapeutics Corp
Total Current Liabilities
Capstone Therapeutics Corp
Total Current Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Capstone Therapeutics Corp
OTC:CAPS
|
Total Current Liabilities
$1.2m
|
CAGR 3-Years
57%
|
CAGR 5-Years
31%
|
CAGR 10-Years
-7%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Total Current Liabilities
$39.4B
|
CAGR 3-Years
6%
|
CAGR 5-Years
10%
|
CAGR 10-Years
16%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Total Current Liabilities
$11.8B
|
CAGR 3-Years
2%
|
CAGR 5-Years
1%
|
CAGR 10-Years
2%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Total Current Liabilities
$25.5B
|
CAGR 3-Years
18%
|
CAGR 5-Years
17%
|
CAGR 10-Years
11%
|
|
|
Astria Therapeutics Inc
NASDAQ:ATXS
|
Total Current Liabilities
$23.5m
|
CAGR 3-Years
54%
|
CAGR 5-Years
27%
|
CAGR 10-Years
12%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Total Current Liabilities
$3.9B
|
CAGR 3-Years
12%
|
CAGR 5-Years
16%
|
CAGR 10-Years
23%
|
|
Capstone Therapeutics Corp
Glance View
Capstone Therapeutics Corp. is a biotechnology company. The company is headquartered in Tempe, Arizona. The firm is focused on development and commercialization of Apo E mimetic peptide AEM-28-14, through its investment in LipimetiX Development LLC. Apolipoprotein E is a 299 amino acid protein, which plays an important role in lipoprotein metabolism. AEM-28 is a 28 amino acid mimetic of Apo E and AEM-28-14, an analog of AEM-28, is a 28 amino acid mimetic of Apo E with an amino-hexanoic acid group and a phospholipid and both contain a domain, which anchors into a lipoprotein surface while also providing the Apo E receptor binding domain, which allows clearance through the heparan sulfate proteoglycan (HSPG) receptors in the liver. AEM-28-14 as an Apo E mimetic, has the potential to enhance the clearance of triglyceride- and cholesterol-rich lipoproteins from the plasma.
See Also
What is Capstone Therapeutics Corp's Total Current Liabilities?
Total Current Liabilities
1.2m
USD
Based on the financial report for Dec 31, 2019, Capstone Therapeutics Corp's Total Current Liabilities amounts to 1.2m USD.
What is Capstone Therapeutics Corp's Total Current Liabilities growth rate?
Total Current Liabilities CAGR 10Y
-7%
Over the last year, the Total Current Liabilities growth was 370%. The average annual Total Current Liabilities growth rates for Capstone Therapeutics Corp have been 57% over the past three years , 31% over the past five years , and -7% over the past ten years .
